SCHEMBL545978

SCHEMBL545978

Nc1cc(CN2CCCCC2)cc(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.60
KDM4E B2RXH2 3/20 0.60
GAA P10253 1/20 0.60
CASP1 P29466 1/20 0.50
CASP5 P51878 1/20 0.50
CYP3A4 P08684 5/20 0.48
CYP2D6 P10635 5/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TP53 P04637 1/20 0.47
HRH3 Q9Y5N1 1/20 0.44
CYP2C19 P33261 3/20 0.44
CYP1A2 P05177 2/20 0.44
USP2 O75604 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
HTT P42858 1/20 0.42
TSHR P16473 4/20 0.42
CYP2C9 P11712 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL545692 0.98 ALDH1A1 (0.58) ALDH1A1KDM4EGAACASP1CASP5
SCHEMBL29967920 0.98 ALDH1A1 (0.58) ALDH1A1KDM4EGAACASP1CASP5
Hydrochloric Acid SCHEMBL30349712 0.97 ALDH1A1 (0.56) ALDH1A1KDM4EGAACASP1CASP5
SCHEMBL4935986 0.95 ALDH1A1 (0.54) ALDH1A1KDM4EGAACASP1CASP5
SCHEMBL31010361 0.88 ALDH1A1 (0.70) ALDH1A1KDM4EGAACASP1CASP5
SCHEMBL6028265 0.86 ALDH1A1 (0.67) ALDH1A1KDM4EGAACASP1CASP5
SCHEMBL446369 0.84 HIF1A (0.52) ALDH1A1KDM4EGAACASP1CASP5
SCHEMBL16907553 0.84 CYP2D6 (0.59) ALDH1A1KDM4EGAACASP1CASP5
SCHEMBL545449 0.84 LMNA (0.53) ALDH1A1KDM4EGAACASP1CASP5
SCHEMBL545422 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EGAACASP1CASP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110687-B2 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-07 US disclosed
US-7652022-B2 N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; NOVARTIS AG (CH) 2010-01-26 US disclosed
EP-1511730-B8 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2009-04-08 EP disclosed
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases FLOERSHEIMER ANDREAS 2006-06-15 US disclosed
EP-1511730-A2 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-09 EP disclosed
WO-2003099771-A2 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases UCK2, PRKDC, PRKACA ALDH1A1 3040/4885KDM4E 1003/4885GAA 1285/4885
US-20070149533-A1 Bicyclic compounds with kinase inhibitory activity MAP3K20, MAP3K1, MAP3K5 ALDH1A1 4226/4885KDM4E 1104/4885GAA 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.